TBG Diagnostics Limited.
http://www.tbgbio.com/en
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From TBG Diagnostics Limited.
Vincerx Blames Stock Plunge On Overheated ADC Expectations
Expectations of robust efficacy from Phase I studies may be unrealistic, but spooked investors have made Vincerz’s cash flow problems even more acute.
France: A European Leader In Rare Diseases
France has long been a European leader in rare diseases, from its scientific research and academic hospitals, through to patient advocacy and regulatory reforms that have encouraged R&D. Its biotech and pharmaceutical industries are now leading the way, discovering the next generation of therapies for patients that are often overlooked.
Deal Watch: Bristol To Link Up With VantAI On Molecular Glue Therapies
Plus deals involving BioVaxys/IMV, Immunome/Ayala, Nascent/Manhattan BioSolutions, AVROBIO/Tectonic, Sanofi/Synthekine, NAYA/Florida Biotechnologies as well as deals in brief and tech transfer agreements.
Deal Watch: Novo Nordisk Builds On Metabolic Strength Acquiring Partner Embark
Bristol and Regeneron sign separate cell therapy technology pacts, plus deals involving Takeda/ImmunoGen, Serina/AgeX, Cybin/Small Pharma, Taiho/Phost’in, Royalty/Ferring and Aardvark/GRI Bio.
Company Information
- Industry
- Research, Analytical Equipment & Supplies
- Services
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Other Names / Subsidiaries
-
- Cellgate
- Epi Pharmaceuticals Inc. (EPI)
- PharmaSynth Pty Ltd
- Progen Industries Limited
- Progen Pharmaceuticals Limited
- Zhangsha ZhangYe Medical Laboratory Corp
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice